Heartflow, a developer of artificial intelligence (AI) tools for the diagnosis of coronary artery disease, has been publicly listed on the Nasdaq stock exchange, raising more than US$364.2 million through an initial public offering (IPO).
The company offered 19,166,667 shares of its common stock at a public offering price of US$19 per share, which began trading on the Nasdaq Global Select Market on 8 August under the ticker symbol HTFL.
The company’s Heartflow One system is a non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed coronary computed tomography angiography (CCTA) pathway.
The AI-driven platform—which includes Roadmap Analysis, FFRCT [fractional flow reserve derived from computed tomography] Analysis and Plaque Analysis—is supported by American College of Cardiology (ACC)/American Heart Association (AHA) chest pain guidelines, and has featured in more than 600 peer-reviewed publications.
Heartflow says that its systems have been used to manage over 400,000 patients worldwide.
